4-(1,1-Dioxo-1,2-thiazolidin-2-yl)-2-methylbenzoic acid → [4-(1,1-Dioxo-1lambda6-isothiazolidin-2-yl)-2-methylphenyl][4-(3-methyl-5-trifluoromethylpyridin-2-yl)piperazin-1-yl]methanone

HRID 2411563ノート

反応式

HRID 2411563 の反応式
[O:1]=[S:2]1(=[O:17])[CH2:6][CH2:5][CH2:4][N:3]1[C:7]1[CH:15]=[CH:14][C:10]([C:11]([OH:13])=O)=[C:9]([CH3:16])[CH:8]=1.[CH3:18][C:19]1[C:20]([N:29]2[CH2:34][CH2:33][NH:32][CH2:31][CH2:30]2)=[N:21][CH:22]=[C:23]([C:25]([F:28])([F:27])[F:26])[CH:24]=1>>[O:17]=[S:2]1(=[O:1])[CH2:6][CH2:5][CH2:4][N:3]1[C:7]1[CH:15]=[CH:14][C:10]([C:11]([N:32]2[CH2:33][CH2:34][N:29]([C:20]3[C:19]([CH3:18])=[CH:24][C:23]([C:25]([F:28])([F:26])[F:27])=[CH:22][N:21]=3)[CH2:30][CH2:31]2)=[O:13])=[C:9]([CH3:16])[CH:8]=1

参加物

3

実験手順

Using 4-(1,1-dioxo-1λ6-isothiazolidin-2-yl)-2-methylbenzoic acid (255 mg) described in Preparation Example 29 and 1-(3-methyl-5-trifluoromethylpyridin-2-yl)piperazine (245 mg) described in Preparation Example 84 and by the reaction and treatment in the same manner as in Example 87, the title compound (230 mg) was obtained.

後処理

  1. customdescribed in Preparation Example 84 and by the reaction and treatment in the same manner as in Example 87

出典と根拠

ORDレコード
ord-4c7587203ae04dabb0b0137ae69deb82
出典データセット
uspto-grants-2014_08
特許番号
US08816079B2

反応ノート

読み込み中…